NanoString Technologies (NSTG) Issues Update on Hyb & Seq Platform at ASHG Annual Meeting
- Euro and global stocks hold Italy-related gains ahead of ECB
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
- GoDaddy (GDDY) to Acquire Host Europe Group in ~$1.8B Deal
- Amazon (AMZN) Could Open Over 2,000 Brick-and Mortar Groceries if Tests Succeed - DJ; Kroger (KR) on Watch
- Trump's corporate tax holiday could spur pharma M&A
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
NanoString Technologies, Inc. (Nasdaq: NSTG) announced an update on the company’s Hyb & Seq platform which is currently in development. Hyb & Seq is a library-free, amplification free single molecule sequencing technique that uses cyclic nucleic acid hybridization of fluorescent molecular barcodes onto native targets. The Hyb & Seq chemistry was first described at the 2016 Advances in Genome Biology and Technology (AGBT) conference. The development program has achieved significant technical milestones and NanoString will present a summary of the Hyb & Seq workflow for targeted cancer panel sequencing at the American Society of Human Genetics (ASHG) Annual Meeting in Vancouver, British Columbia. The workflow will be described in poster #2891/T, “From FFPE Tissue to Targeted Multiplex Panel Sequencing in Less than 60 Minutes Using Hyb & Seq™ Chemistry,” at 2:00pm PT on Thursday, October 20th.
Hyb & Seq chemistry is designed to provide unprecedented simplicity of workflow and is compatible with a wide variety of clinical samples such as FFPE, fresh frozen tissue, blood and fine needle aspirates, across a wide variety of applications including RNA and DNA sequencing with both short and long read capabilities. Hyb & Seq chemistry offers the potential for the simplest sequencing workflow, which NanoString believes is critical for driving adoption in clinical applications.
“NanoString’s Hyb & Seq chemistry has the potential to accelerate the adoption of Next-Generation Sequencing in clinical applications by vastly simplifying the workflow and minimizing the hands-on-time, personnel training, and infrastructure required to set-up and maintain a state-of-the-art NGS laboratory,” stated Joseph Beechem, Ph.D., Senior Vice President of R&D at NanoString. “We’re making excellent progress and plan to provide our next status report at AGBT 2017 in February.”
In addition, NanoString will be hosting a lunch seminar at ASHG to provide an update on the company’s 3D Biology™ program. The presentation, “3D Biology™: Simultaneous Single-Molecule Quantification of DNA (SNVs), mRNA, Fusion Genes and Proteins Using Molecular Barcodes,” will be held in Room 10 of the East Building, on Wednesday, October 19th from 1:00–2:30pm Pacific Time. Collaborators from MD Anderson Cancer Center and Fred Hutchinson Cancer Research Center will present data that demonstrate the robustness and sensitivity of the assay across a wide range of FFPE samples. NanoString will be showcasing the nCounter® Analysis System at booth #512 at the Vancouver Convention Centre.
The company will also be presenting the following posters at the ASHG Annual Meeting.
Title: Oncology Biomarker Development: Simultaneous Digital Counting of Nucleic Acids and Proteins at 800-plexDate/Time: Thursday October 20th, from 3:00 - 4:00pm PTAuthors: E. Manrao, D. Kim, et. al.Program Number: 2876/T
Title: Multiplex Profiling of Cancer Driver Mutations: Detection of Single Nucleotide Variants (SNV) and Small Indels from Small Amounts of FFPE Sample on the nCounter® Analysis SystemDate/Time: Friday October 21st from 2:00 - 3:00pm PTAuthors: M. Ross, J. Lee, et. al. Program Number: 2895/F
Title: Multiplex Detection of Lung Cancer Driver Mutations: Simultaneous Assay of Single Nucleotide Variants (SNV) and Fusion Transcripts From Small Amounts of FFPE Samples on the nCounter® Analysis SystemDate/Time: Thursday October 20th from 3:00 - 4:00pm PTAuthors: G. Meredith, J. Kargl, et. al.Program Number: 2894/T
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NanoString (NSTG) Reports Presentation of Multiple Prosigna/PAM50 and Immuno-Oncology Studies at Breast Cancer Symposium
- TG Therapeutics (TGTX) Hits Target Enrollment in GENUINE Phase 3
- SAGE Therapeutics (SAGE) Expedites Development of SAGE-547 Following FDA Meeting Minutes
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!